Meeting
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.
Authors
James M. G. Larkin
The Royal Marsden NHS Foundation Trust, London, United Kingdom
James M. G. Larkin , Michael S. Gordon , Fiona Thistlethwaite , Paul D. Nathan , Brian I. Rini , Marcella Martignoni , Michael Shnaidman , Chiara Chiruzzi , Alessandra Di Pietro , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02493751
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS4580)
DOI
10.1200/JCO.2016.34.15_suppl.TPS4580
Abstract #
TPS4580
Poster Bd #
199a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).
First Author: Toni K. Choueiri
Poster
2022 ASCO Genitourinary Cancers Symposium
Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.
First Author: Ajeet Gajra
Poster
2020 ASCO Virtual Scientific Program
SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates.
First Author: Benjamin Maurice Solomon
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Avelumab flat dose regimen: Justification for use in advanced renal cell carcinoma (aRCC).
First Author: John B. A. G. Haanen